首页> 外文期刊>Immunology, endocrine & metabolic agents in medicinal chemistry. >Lipoprotein(a) is a Therapeutic Target for Cardiovascular Disease
【24h】

Lipoprotein(a) is a Therapeutic Target for Cardiovascular Disease

机译:脂蛋白(a)是心血管疾病的治疗靶标

获取原文
获取原文并翻译 | 示例
           

摘要

Abstract: Lipoprotein(a) [Lp(a)] is known as an independent risk factor for cardiovascular diseases (CVD). Lp(a) is a unique lipoprotein consisting of the glycoprotein apolipoprotein(a) [apo(a)] covalently linked to apolipoproteinB-100 (apoB) in low-density lipoprotein (LDL) by a single disulfide bond. Although Lp(a) level is hugely variable and under strict genetic control, largely by apo(a) gene with kringle-4 type2 repeats, elevated level of plasma Lp(a) is correlated with CVD. Smaller isoforms with fewer kringle-4 repeats are associated with higher plasma Lp(a) level, leading to an increased risk for CVD. Lipid lowering agents (i.e. statins) have little or no effect on plasma Lp(a) level. Although it was reported that administration of niacin or estrogen may reduce the Lp(a) levels, there are no specific agents for the reduction of plasma Lp(a). In this review, we put together recent evidence and describe the overview of Lp(a) with the future direction.
机译:摘要:脂蛋白(a)[Lp(a)]被称为心血管疾病(CVD)的独立危险因素。 Lp(a)是一种独特的脂蛋白,由糖蛋白载脂蛋白(a)[apo(a)]通过单二硫键与低密度脂蛋白(LDL)中的载脂蛋白B-100(apoB)共价连接。尽管Lp(a)的水平变化很大,并且在严格的遗传控制下,很大程度上由具有kringle-4 type2重复的apo(a)基因引起,血浆Lp(a)的升高与CVD相关。具有较少kringle-4重复序列的较小异构体与较高血浆Lp(a)水平相关,从而导致CVD风险增加。降脂剂(即他汀类药物)对血浆Lp(a)水平几乎没有影响。尽管据报道烟酸或雌激素的给药可以降低Lp(a)的水平,但尚无用于降低血浆Lp(a)的特异性药物。在这篇综述中,我们汇总了最近的证据并描述了Lp(a)的概述以及未来的方向。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号